Just this morning, the Supreme Court issued its slip opinion on Hikma v. Amarin, the most recent “skinny-label” case, and it did so unanimously. Justice Jackson, writing for all nine, reversed the Federal Circuit and held that Amarin’s lawsuit against the generic manufacturer Hikma cannot survive a motion to dismiss. I had planned to spread this story across a short series (with the first one going live today — the life of an academic!), yet the Court’s timing collapsed it into one post. So let me take it from the top: how the generic-drug bargain works, how a fish-oil pill turned into a Supreme Court case, what the Justices made of it, and why this quiet dispute is one of the more consequential drug-pricing rulings in years.
The skinny-label bargain
First: let me briefly introduce the regulation that produces the so-called “skinny label.” The Hatch-Waxman Act of 1984 created the modern system for generic-drug approval. Before the Hatch-Waxman Act, a generic manufacturer had to run its own full set of clinical trials to demonstrate safety and efficacy, essentially repeating the brand company’s work at enormous cost. The Act created the Abbreviated New Drug Application (ANDA), which lets a generic manufacturer rely on the brand’s clinical data by showing only that its product is “bioequivalent” to the brand — that it delivers the same active ingredient to the body in the same way. As a result, roughly ninety percent of prescriptions in this country are now filled with generics. And competition keeps pushing those prices down: the FDA has found that once six or more generic manufacturers share a market, the generic typically sells for more than ninety-five percent below the brand’s pre-competition price.
But a single drug can have multiple approved uses, some still under patent protection and some not. Congress addressed this through what is known as the “section viii statement.” The provision allows a generic manufacturer to obtain FDA approval for fewer than all of a brand drug’s approved indications by carving out the patented uses from its label. The result is a “skinny label”: a label covering only the unpatented indications. The generic reaches the market and competes on price for the unpatented uses, while the brand retains exclusivity over the patented ones.
For all the jargon, the skinny-label pathway is the core mechanism Congress built so that a patent on one use of a drug wouldn’t block generic competition for its other uses. The pathway makes more sense, though, once you see the other routes a generic can take.
When a brand wins FDA approval, it lists its patents in the FDA’s Orange Book, the public directory that tells generics which patents cover which drug. A generic filing an ANDA must address every listed patent, and it has a menu of choices: certify that no patent is listed or that the patents have expired; wait for expiry and then launch (slow, but no litigation); or file a “Paragraph IV” certification challenging the patent as invalid or not infringed. Paragraph IV is the high-risk, high-reward path: the brand almost always sues, and that lawsuit triggers an automatic thirty-month stay on the generic’s approval, but the first filer can earn 180 days of market exclusivity against other generics.
Section viii is the alternative. The generic does not challenge the patent at all; it carves the patented use out of its label and sells only for the unpatented indications. No patent challenge means no thirty-month stay and no up-front litigation. It is supposed to be the fast, safe pathway. The stakes in Hikma are, in short, whether the skinny-label pathway remains fast and safe, or becomes fast and risky.
Enter Vascepa
Amarin Pharma makes a drug called Vascepa, a prescription fish-oil derivative that is, essentially, the company’s entire business. High triglycerides are common enough that many readers have probably had a doctor flag their own, or know someone who has, and Vascepa is the prescription-strength, purified form of omega-3 (not the fish oil on the drugstore shelf!) used to treat them. The FDA approved Vascepa for two different uses. The first, back in 2012, is for dangerously high triglycerides, which at extreme levels can trigger conditions like pancreatitis. The second, added in 2019 after a clinical trial involving some 8,000 patients, reduces cardiovascular risk in high-risk patients already taking a statin. Only that second, cardiovascular use is patented, and by the time this dispute arose, this second use accounted for more than 75 percent of Vascepa’s sales.
Vascepa is not cheap. The brand runs roughly $300 to $500 a month at the pharmacy — well over $4,000 a year for a patient paying out of pocket. The generic, icosapent ethyl, can be found for under $100 a month with a pharmacy discount card. That gap, multiplied across an entire patient population, is why the timing of generic entry matters so much.
As a quick side note: when Hikma first filed its application back in 2016, the only approved use was the original triglyceride indication, and Hikma challenged Amarin’s patents on it head-on with a Paragraph IV certification. Amarin sued, and a court invalidated those patents, clearing the original use entirely. Only the later cardiovascular patents survived, which is why, by the time Hikma launched, the carve-out came down to that single use.
Hikma then did exactly what the skinny-label pathway contemplates. It carved the patented cardiovascular use out of its label with a section viii statement and sought approval only for the original, now-unpatented use. The FDA signed off in May 2020. So far, this is Hatch-Waxman working precisely as designed.
The trouble started, at least from Amarin’s viewpoint, with how Hikma marketed the product. Hikma called the drug a “generic version of Vascepa” and pointed to the total U.S. sales of Vascepa — a figure that swept in the patented use. Hikma’s website listed the product under a broad therapeutic category and noted that it was rated therapeutically equivalent to the brand. Still, Hikma’s launch materials said the product was “not approved for any other indication” beyond the one it was cleared for, and its website carried a disclaimer to the same effect.
Amarin’s theory was that, disclaimers and all, Hikma’s overall message that the product was the “generic version of Vascepa,” paired with sales numbers driven by the patented use, still nudged doctors toward prescribing it for the patented cardiovascular indication. Less than one month after Hikma launched, Amarin sued for what the law calls induced infringement. One fact is hard to ignore: several other companies sell the very same generic compound, but Amarin’s inducement claim went after only one of them. Hikma.
Three judges, three answers
What makes the case interesting is that careful judges kept disagreeing about it. A magistrate judge looked at Amarin’s complaint and thought it should survive. The district judge disagreed and threw it out with prejudice, finding that none of Hikma’s statements were active steps to encourage infringement. The Federal Circuit then disagreed with him, reviving the case on the theory that it was at least plausible that a physician could read Hikma’s statements as encouragement to infringe, and that the whole picture had to be judged in its totality. Three rounds, and no consensus, on the same set of facts. In January, the Supreme Court agreed to break the tie.
How the argument went
At argument in April, three positions emerged. Hikma’s counsel asked for a clear rule: active inducement should require, in his phrase, “a clear message that necessarily promotes infringement,” a standard he grounded in the Court’s 2005 decision in MGM v. Grokster. His strongest points were structural. A generic’s label must mirror the brand’s by law, so punishing Hikma for what its label retained punishes legally compelled conduct; and the Federal Circuit had effectively required Hikma to actively discourage infringement, which inverts a statute that asks only whether it encouraged infringement. He warned that if these post-launch suits routinely survive, no rational generic will use section viii at all, pointing to a comparable case against Teva that produced a $235 million award.
The United States, supporting Hikma on narrower ground, asked only for faithful application of existing law, with no Hatch-Waxman-specific rule, and added that a carved-out label should carry no evidentiary weight at all, since punishing the compliance Congress required punishes the behavior Congress wanted. Brands are not defenseless, the government noted; they can sue the payers whose reimbursement decisions actually drive off-label use.
Amarin, for its part, tried to shrink the case, calling it a narrow pleading dispute about one company’s marketing rather than a referendum on the skinny label. The bench seemed wary of writing any new rule, and once all three lawyers conceded that no new doctrine was needed, a few Justices wondered aloud whether the case was worth deciding at all. If I were a betting woman, and I am not (and I promise I had this written prior to the opinion dropping this morning!), I would have put money on a narrow ruling for Hikma on ordinary pleading standards, no sweeping doctrine, perhaps even a vacate-and-remand.
What the Court held
That is essentially what happened, only more decisively. The Court reversed the Federal Circuit, 9-0. The heart of the opinion is a distinction that sounds technical but does real work: the question is whether Hikma actively encouraged infringement, not whether a doctor could read Hikma’s statements as encouragement. Statements designed to stimulate infringement, Justice Jackson wrote, are a narrower category than statements that merely could. Inducement under § 271(b) takes affirmative, purposeful steps; it does not reach the ordinary acts of selling a product that someone else might put to an infringing use.
By that measure, Amarin’s theory failed at every turn. Several of Hikma’s statements had an obvious innocent explanation: Hikma was complying with the law. A generic’s label must, by statute, match the brand’s except for the carved-out use — the duty of sameness — so Hikma could not be faulted for what its label retained. And describing a product as a “generic version” or “generic equivalent” of the brand is, as the Court put it, normal industry practice. The Court refused to put generic makers between a rock and a hard place by turning compliance with the law into the building blocks of illegal conduct. Other parts of Amarin’s case rested on what Hikma left unsaid, but omissions and silence, the Court held, cannot carry an active-inducement claim. And what remained was simply too vague to count: a patient leaflet’s side-effect warning, a website listing a broad therapeutic category and an “AB” equivalence rating, and sales figures in press releases plainly aimed at investors rather than doctors. That last theory, the Court observed, required a chain of inferences that was possible but not plausible, and possible has never been the standard.
The Court also turned away both sides’ attempts to move the law. It rejected Amarin’s expansive “could be read as encouragement” approach, but it also rejected Hikma’s position that inducement must be express; implicit encouragement can qualify, so long as it is clear and affirmative. And in a pointed footnote, the Court disapproved the Federal Circuit’s recent habit, visible in cases like its GSK v. Teva decision, of asking how providers might read a generic’s statements rather than whether the generic actually encouraged infringement. That was the very trend that had been leaving skinny-label defendants increasingly exposed.
Why this matters more than the statehouse
Here is why I think this modest-looking case matters more than the louder drug-pricing battles in state capitols. The single biggest determinant of what a patient pays for a drug is whether a generic exists, and when generics arrive is governed by federal patent law, not by state regulation. States have been busy on the back end: more than twenty have passed transparency laws, at least ten have stood up affordability boards, and in October 2025 Colorado became the first state to set an enforceable cap on a specific drug, limiting payment for the arthritis biologic Enbrel, though that cap does not take effect until 2027, if it survives the maker’s constitutional challenge. Here in Wisconsin, legislators have tried more than once to create such a board, and Governor Evers wrote one into his latest budget, but none has survived the legislature. Lots of motion, little movement on price.
The skinny label is a front-end lever, and a powerful one. A 2024 research letter in the Annals of Internal Medicine estimated that skinny-label generics saved Medicare Part D about $14.6 billion across just fifteen drugs between 2015 and 2021. Had the Court gone the other way and blessed the Federal Circuit’s approach, every generic weighing a section viii carve-out would have had to price in the risk of a post-launch inducement suit, with damages that can run into the hundreds of millions, and some would have walked away from the pathway altogether for the highest-value drugs. Congress has bipartisan bills aimed at the patent tactics that delay competition, but they keep stalling. For now, the most powerful lever on drug prices runs through federal patent law, and a unanimous Supreme Court just used it to keep generics flowing.
The case will return to the lower courts, but Amarin’s theory, as it built it, is finished, and because the original dismissal was with prejudice, its room to start over looks slim. The larger takeaway is simpler. The skinny label survives, and with it one of the few dependable tools we have for getting cheaper drugs to patients sooner. For a fish-oil pill, that is a surprisingly large legacy.